{"schema_version":"secwatch.filing_event.v1","accession":"0000885725-26-000031","form_type":"8-K","ticker":"BSX","cik":"0000885725","company_name":"BOSTON SCIENTIFIC CORP","filed_at":"2026-04-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.870679+00:00","generated_at":"2026-05-15T05:00:09.570769+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Boston Scientific Q1 2026 net sales $5.20B (+11.6% reported), adj EPS $0.80 (guidance $0.78-$0.80)","bullets":["GAAP EPS $0.90 vs $0.45 YoY; adjusted EPS $0.80 vs $0.75 YoY, at top of guidance.","Cardiovascular segment net sales $3.50B (+13.5% reported); MedSurg $1.70B (+7.8% reported).","FY2026 guidance: organic growth 6.5-8.0%; adj EPS $3.34-$3.41. Q2: organic growth 5.0-7.0%; adj EPS $0.82-$0.84.","WATCHMAN FLX trial (CHAMPION-AF) met all endpoints; FARAPULSE PFA showed superior long-term AF outcomes.","Acquired Valencia Technologies (eCoin system for urge incontinence); elected Cathy Smith and Christophe Weber to board."],"urls":{"canonical":"https://secwatch.observer/filing/0000885725-26-000031","json":"https://secwatch.observer/filing/0000885725-26-000031.json","markdown":"https://secwatch.observer/filing/0000885725-26-000031.md","text":"https://secwatch.observer/filing/0000885725-26-000031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/885725/000088572526000031/0000885725-26-000031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/885725/000088572526000031/bsx-20260422.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T05:00:09.570769+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5d7ed3115df4e861bbf4c70c44845378d0a42584","claim":"BOSTON SCIENTIFIC CORP reported first quarter ended March 31, 2026 results: revenue $5.203 billion, net income $1.341 billion or $0.90 per share (EPS), EPS $0.80.","evidence_excerpt":"(EX-99.1) --- Boston Scientific announces results for first quarter 2026 Marlborough, Mass. (April 22, 2026) -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.203 billion during the first quarter of 2026, growing 11.6 percent on a reported basis and 9.4 percent on an operational 1 and organic 2 basis, all compared to the prior year period. The","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/885725/000088572526000031/0000885725-26-000031-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Revenue","value":"$5.203 billion"},{"label":"Net income","value":"$1.341 billion or $0.90 per share (EPS)"},{"label":"EPS","value":"$0.80"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}